Cargando…

Circulating cell‐free messenger RNA enables non‐invasive pan‐tumour monitoring of melanoma therapy independent of the mutational genotype

BACKGROUND: Plasma‐derived tumour‐specific cell‐free nucleic acids are increasingly utilized as a minimally invasive, real‐time biomarker approach in many solid tumours. Circulating tumour DNA of melanoma‐specific mutations is currently the best studied liquid biopsy biomarker for melanoma. However,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Albrecht, Lea Jessica, Höwner, Anna, Griewank, Klaus, Lueong, Smiths S., von Neuhoff, Nils, Horn, Peter A., Sucker, Antje, Paschen, Annette, Livingstone, Elisabeth, Ugurel, Selma, Zimmer, Lisa, Horn, Susanne, Siveke, Jens T., Schadendorf, Dirk, Váraljai, Renáta, Roesch, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626658/ https://www.ncbi.nlm.nih.gov/pubmed/36320118 http://dx.doi.org/10.1002/ctm2.1090

Ejemplares similares

Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations
por: Cosgarea, Ioana, et al.
Publicado: (2017)

Is there a role for immune checkpoint blockade in metastatic uveal melanoma?
por: Schilling, Bastian, et al.
Publicado: (2015)

Genetic and Methylation Analysis of CTNNB1 in Benign and Malignant Melanocytic Lesions
por: Zaremba, Anne, et al.
Publicado: (2022)

Genetic and Clinical Characteristics of ARID1A Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient Survival
por: Thielmann, Carl Maximilian, et al.
Publicado: (2022)

Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
por: Váraljai, Renáta, et al.
Publicado: (2023)

Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
por: Váraljai, Renáta, et al.
Publicado: (2023)

Single-strand DNA library preparation improves sequencing of formalin-fixed and paraffin-embedded (FFPE) cancer DNA
por: Stiller, Mathias, et al.
Publicado: (2016)

Analysis of SDHD promoter mutations in various types of melanoma
por: Scholz, Simone L., et al.
Publicado: (2015)

Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition – Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 Immunohistochemistry
por: Placke, Jan-Malte, et al.
Publicado: (2021)

Plasma Next Generation Sequencing and Droplet Digital-qPCR-Based Quantification of Circulating Cell-Free RNA for Noninvasive Early Detection of Cancer
por: Metzenmacher, Martin, et al.
Publicado: (2020)

Integrative Genomic Analyses of Patient-Matched Intracranial and Extracranial Metastases Reveal a Novel Brain-Specific Landscape of Genetic Variants in Driver Genes of Malignant Melanoma
por: Váraljai, Renáta, et al.
Publicado: (2021)

Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma
por: Placke, Jan-Malte, et al.
Publicado: (2021)

STAT3 Single Nucleotide Polymorphism rs4796793 SNP Does Not Correlate with Response to Adjuvant IFNα Therapy in Stage III Melanoma Patients
por: Schrama, David, et al.
Publicado: (2014)

Lack of SF3B1 R625 mutations in cutaneous melanoma
por: Schilling, Bastian, et al.
Publicado: (2013)

Innate immune receptor signaling induces transient melanoma dedifferentiation while preserving immunogenicity
por: Thier, Beatrice, et al.
Publicado: (2022)

The Prognostic Relevance of PMCA4 Expression in Melanoma: Gender Specificity and Implications for Immune Checkpoint Inhibition
por: Hegedüs, Luca, et al.
Publicado: (2022)

Kutanes Angiosarkom mit klinischem Bild eines Quincke-Ödems
por: Albrecht, M., et al.
Publicado: (2021)

Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?
por: Zaremba, Anne, et al.
Publicado: (2019)

Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade: A Case Report
por: Matull, Johanna, et al.
Publicado: (2020)

Frequent Occurrence of NRAS and BRAF Mutations in Human Acral Naevi
por: Jansen, Philipp, et al.
Publicado: (2019)

The clinical utility of cfRNA for disease detection and surveillance: A proof of concept study in non‐small cell lung cancer
por: Metzenmacher, Martin, et al.
Publicado: (2022)

The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma
por: Albrecht, Lea Jessica, et al.
Publicado: (2023)

TERT Promoter Mutations Are Frequent in Cutaneous Basal Cell Carcinoma and Squamous Cell Carcinoma
por: Griewank, Klaus G., et al.
Publicado: (2013)

Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma – analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM
por: Placke, Jan-Malte, et al.
Publicado: (2023)

GNA14, GNA11, and GNAQ Mutations Are Frequent in Benign but Not Malignant Cutaneous Vascular Tumors
por: Jansen, Philipp, et al.
Publicado: (2021)

Combined multimodal ctDNA analysis and radiological imaging for tumor surveillance in Non-small cell lung cancer
por: Metzenmacher, Martin, et al.
Publicado: (2021)

Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions
por: Sucker, Antje, et al.
Publicado: (2017)

B-RAF and N-RAS Mutations Are Preserved during Short Time In Vitro Propagation and Differentially Impact Prognosis
por: Ugurel, Selma, et al.
Publicado: (2007)

SERPINB1 expression is predictive for sensitivity and outcome of cisplatin-based chemotherapy in melanoma
por: Willmes, Christoph, et al.
Publicado: (2016)

BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes
por: Peiffer, Lukas, et al.
Publicado: (2020)

Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies
por: Utikal, Jochen, et al.
Publicado: (2007)

Persister state-directed transitioning and vulnerability in melanoma
por: Chauvistré, Heike, et al.
Publicado: (2022)

COVID-19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment: A prospective singlecenter study investigating seroconversion rates
por: Lodde, Georg C., et al.
Publicado: (2022)

Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib
por: Brase, Jan C., et al.
Publicado: (2021)

Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma
por: Ferdinandus, Justin, et al.
Publicado: (2022)

A Genome-Wide Tethering Screen Reveals Novel Potential Post-Transcriptional Regulators in Trypanosoma brucei
por: Erben, Esteban D., et al.
Publicado: (2014)

NF1 mutations in conjunctival melanoma
por: Scholz, S. L., et al.
Publicado: (2018)

Personalised proteome analysis by means of protein microarrays made from individual patient samples
por: Syafrizayanti, et al.
Publicado: (2017)

TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours
por: Griewank, K G, et al.
Publicado: (2013)

Corticosteroids Augment BRAF Inhibitor Vemurafenib Induced Lymphopenia and Risk of Infection
por: Sondermann, Wiebke, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_r05eqn43a9dnnkk2hjch9khfsj